What Xaira Therapeutics does
Xaira Therapeutics is a privately held, AI-native biotechnology company focused on re-engineering drug discovery and development end-to-end using “predictive and agentic” AI. The company describes its core approach as integrating (1) advanced machine-learning research, (2) large-scale biological data generation spanning molecular-to-human scales, and (3) robust therapeutic product development across multiple modalities. Xaira’s stated goal is to make biology more computable and to progressively connect causal biological understanding to therapeutic design and patient outcomes, using each lab/clinical step as an input to improved models.
Strategically, Xaira is positioned as a platform-and-pipeline hybrid: it aims to build “virtual cell” and related causal modeling capabilities (for target identification, mechanism-of-action learning, patient matching, and toxicity predictions) while also applying those capabilities to develop a therapeutic pipeline intended to advance toward clinical stages. Publicly disclosed milestones in 2025–2026 emphasize the company’s emphasis on large causal perturbation datasets and high-capacity models—especially its “X-Cell” virtual cell model and the underlying “X-Atlas” perturb-seq datasets.